Bipharm LLC

2:15 PM - 2:30 PM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Bipharm is an innovative preclinical stage biotech company developing potent small molecules
that inhibits chromosomal instability in cancer by the interaction between Hec1 and Nek2 proteins. Those proteins play a pivotal role in the cell division process of healthy cells helping the correct segregation of chromosomes during mitosis. Overexpression of Hec1 and Nek2 results in chromosomal instability (CIN) and aneuploidy in cancer cells. Both proteins are frequently overexpressed in aggressive types of solid tumors, such as triple-negative breast cancer (TNBC), recurrent/resistant colorectal cancer, liver cancer, gastric cancer, pancreatic cancer, lung cancers, and glioblastoma.
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
BP-001, inhibits Hec1 and Nek2 causing Nek2 degradation
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided